The reduction in the price target from $130 to $81 by a reputable analyst firm like RBC Capital could lead to a negative short-term impact on QuidelOrtho's stock price. Investors often view such adjustments as a signal of potential concerns about the company's future performance, even though the Outperform rating was maintained. This could result in decreased investor confidence and a possible decline in stock price in the short term.